When was PulseSight founded?

PulseSight was founded in 2008 and raised its 1st funding round 4 years after it was founded.

Where is PulseSight located?

PulseSight is headquartered in Paris, France.

Who is the current CEO of PulseSight?

Patricia Zilliox of PulseSight.

How many employees does PulseSight have?

As of May 31, 2026, the latest employee count at PulseSight is 10.

Is PulseSight a funded company?

PulseSight is a funded company, having raised a total of $54.2M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 01, 2012.

When was the latest funding round of PulseSight?

PulseSight's latest funding was a $***** Series B round on Feb 28, 2024, with participation from 3 investors. Its primary sector is Ophthalmology. Globally, the Ophthalmology sector has seen $1.66B in funding in 2026 to date.

Where does PulseSight rank among its competitors?

PulseSight ranks 5th amongst 37 active competitors, of which 18 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Epicrispr Bio, which secured $177M in Aug, 2026.

Who are the top competitors of PulseSight?

PulseSight's top competitors include Epicrispr Bio, Tenpoint Therapeutics and Ray Therapeutics. Among them, Epicrispr Bio secured the most recent funding round in August, 2026.

PulseSight - 2026 Company Profile, Team, Funding & Competitors

PulseSight is a series B company based in Paris (France), founded in 2008 by Francine Behar- Cohen. It operates as a Developer of non-viral minimally invasive gene therapies for retinal diseases. PulseSight has raised $54.2M in funding from investors like Boehringer Ingelheim Venture Fund, Korea Investment Holdings and ND Capital. The company has 37 active competitors, including 18 that are funded. Its top competitors include companies like Epicrispr Bio, Tenpoint Therapeutics and Ray Therapeutics.

Company Details

Developer of non-viral minimally invasive gene therapies for retinal diseases. The company is pioneering a unique approach to administer disease-modifying genes through its proprietary electro-transfection delivery device. The company's programs include PST-809, for wet Age-Related Macular Degeneration and PST-611 for dry Age-Related Macular Degeneration.

Website: pulsesight.com
Email ID: *****@pulsesight.com
Phone Number: +33 **********

Key Metrics

Founded Year

2008

Location

Paris, France

Stage

Series B

Total Funding

$54.2M in 6 rounds

Latest Funding Round

Series B, Feb 28, 2024, $*****

Investors

Boehringer Ingelheim Venture Fund & 11 more

Ranked

5^th among 37 active competitors

Employee Count

10 as on May 31, 2026

Similar Companies

Epicrispr Bio & 36 more

View PulseSight's full profile

PulseSight has raised a total funding of $54.2M over 6 rounds. Its first funding round was on Jan 01, 2012. Its latest funding round was a Series B round on Feb 28, 2024 for $*****. 3 investors participated in its latest round. PulseSight has 12 institutional investors.

Here is the list of recent funding rounds of PulseSight:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 28, 2024	6164012	Series B	5741340	7988348	3306943	4257283
Aug 04, 2021	4445893	Series B	6932976	5446559	2493525	6466533
Jan 08, 2020	2012485	Series B	2844248	7991087	Boehringer Ingelheim Venture Fund	Pontifax & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of PulseSight's funding rounds and investors

The founders of PulseSight is Francine Behar- Cohen.

Here are the details of PulseSight's key team members:

Francine Behar- Cohen: Founder & CHIEF INNOVATION OFFICER of PulseSight and founder of 1 other company.
Patricia Zilliox: CEO of PulseSight.

View details of PulseSight's Founder profiles and Board Members

PulseSight's employee count trend

PulseSight has 10 employees as of May 26. Here is PulseSight's employee count trend over the years:

Uncover PulseSight's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PulseSight include Epicrispr Bio, Tenpoint Therapeutics and Ray Therapeutics. Here is the list of Top 10 competitors of PulseSight, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Epicrispr Bio 2018, San Francisco (United States), Series C	Developer of therapeutics for multiple disease	$245M	Octagon Capital Advisors, Ally Bridge Group ... & 10 others	62/100
2nd	Tenpoint Therapeutics 2019, Warren (United States), Series B	Developer of engineered cell-based therapeutics to restore vision	$155M	EQT, Janus Henderson Investors & 20 others	61/100
3rd	Ray Therapeutics 2021, Berkeley (United States), Series B	Developer of therapeutics for degenerative retinal diseases	$231M	Janus Henderson Investors, 4Bio Capital & 11 others	58/100
4th	Character Biosciences 2019, San Francisco (United States), Series B	Developer of therapeutics for the treatment of age-related eye diseases	$120M	Innovation Endeavors, aMoon & 12 others	57/100
5th	PulseSight 2008, Paris (France), Series B	Developer of non-viral minimally invasive gene therapies for retinal diseases	$54.2M	Pontifax, ND Capital & 10 others	56/100
6th	Ashvattha Therapeutics 2015, Redwood City (United States), Series B	Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases	$120M	Tribe Capital, Natural Capital & 11 others	56/100
7th	Seabelife 2019, Roscoff (France), Seed	Developer of small-molecule drugs that simultaneously inhibit necroptosis and ferroptosis	$8.32M	iXLife Capital, Bpifrance & 9 others	53/100
8th	Nanoscope Therapeutics 2017, Bedford (United States), Series B	Provider of nanoscope therapeutic solutions for eye diseases	$12.8M	NIH, AG Collective Capital	53/100
9th	Cirrus Therapeutics 2022, Cambridge (United States), Seed	Developer of therapies designed to extend ocular healthspan and restore vision	$11M	Clavystbio, SEEDS Capital & 2 others	49/100
10th	RhyGaze 2024, Basel (Switzerland), Series A	Developer of gene therapies to restore vision	$97.2M	Google Ventures, BioGeneration Ventures & 3 others	46/100